Consensus Revvity, Inc.

Equities

RVTY

US7140461093

Real-time Estimate Cboe BZX Other stock markets 02:18:10 2024-09-13 pm EDT			5-day change	1st Jan Change
121.24 ^USD	+0.91%		+4.95%	+10.80%

Sep. 10	Transcript : Revvity, Inc. Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 12:15 PM
Sep. 04	Transcript : Revvity, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 08:45 AM

Evolution of the Average Target: Revvity, Inc.

Evolution of the Target Price: Revvity, Inc.

Changes in Analyst Recommendations: Revvity, Inc.

b0ecb28db0d32d6f32edd55fb3.2ZX2BgnH-dWnAHuwPCoDGuH3fSXWdAAo1u9FIBmQ0dM.qdCbcmD1qIaRcAH6CW1wKszPTl-7OVVOt4Andn_jk4rryoZhZ4TUj4plEA~dfa21cb6a5b590f6c6415d5cae5e338e

Analysts' recommendations: Revvity, Inc.

Wells Fargo Initiates Revvity at Equalweight With $130 Price Target	Aug. 28	MT
UBS Adjusts Revvity Price Target to $140 From $120, Maintains Neutral Rating	Jul. 30	MT
Bernstein Adjusts Price Target on Revvity to $145 From $121	Jul. 30	MT
TD Cowen Adjusts Price Target on Revvity to $141 From $130	Jul. 30	MT
Goldman Sachs Adjusts Price Target on Revvity to $130 From $120	Jul. 30	MT
JPMorgan Adjusts Price Target on Revvity to $120 From $105	Jul. 30	MT
Barclays Adjusts Price Target on Revvity to $125 From $115	Jul. 30	MT
Stifel Adjusts Price Target on Revvity to $120 From $110	Jul. 30	MT
Citigroup Adjusts Price Target on Revvity to $145 From $135	Jul. 30	MT
Raymond James Adjusts Price Target on Revvity to $144 From $127	Jul. 30	MT
Leerink Partners Adjusts Price Target on Revvity to $130 From $125	Jul. 30	MT
Baird Adjusts Price Target on Revvity to $136 From $127	Jul. 30	MT
KeyBanc Raises Price Target on Revvity to $132 From $126	Jul. 29	MT
Evercore ISI Adjusts Price Target on Revvity to $132 From $126	Jul. 29	MT
Nephron Adjusts Price Target on Revvity to $134 From $124	Jul. 29	MT
Bernstein Adjusts Price Target on Revvity to $121 From $123	Jul. 18	MT
Leerink Initiates Revvity at Outperform With $125 Price Target	Jul. 08	MT
Barclays Trims Price Target on Revvity to $115 From $116	Jun. 27	MT
TD Cowen Adjusts Price Target on Revvity to $130 From $123	Apr. 30	MT
JPMorgan Adjusts Price Target on Revvity to $105 From $100, Neutral Rating Maintained	Apr. 30	MT
Baird Adjusts Price Target on Revvity to $127 From $126	Apr. 30	MT
Bernstein Adjusts Price Target on Revvity to $123 From $125, Keeps Outperform Rating	Apr. 30	MT
Nephron Adjusts Revvity's Price Target to $124 From $120	Apr. 29	MT
Bernstein Adjusts Price Target on Revvity to $125 From $126	Apr. 22	MT
Baird Adjusts Price Target on Revvity to $126 From $123	Apr. 22	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	REVVITY, INC.					+11.42%
	THERMO FISHER SCIENTIFIC INC.					+2.98%
	DANAHER CORPORATION					+5.16%
	INTUITIVE SURGICAL, INC.					-2.04%
	BOSTON SCIENTIFIC CORPORATION					+4.09%
	SIEMENS HEALTHINEERS AG					+18.73%
	EDWARDS LIFESCIENCES CORPORATION					+16.57%
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.					+57.63%
	AGILENT TECHNOLOGIES, INC.					+8.15%
	GE HEALTHCARE TECHNOLOGIES INC.					+8.58%
	Average					+13.13%
	Weighted average by Cap.					+7.04%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

120.15USD

Average target price

133.87USD

Spread / Average Target

+11.42%

High Price Target

162.00USD

Spread / Highest target

+34.83%

Low Price Target

120.00USD

Spread / Lowest Target

-0.12%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

TD Cowen
JPMorgan Chase
Baird
Bernstein
Nephron Research
KeyBanc Capital Markets
Raymond James
BofA Securities
Barclays
UBS
Evercore ISI
Wells Fargo Securities
Goldman Sachs
Citigroup
Stifel Nicolaus
Cowen
Credit Suisse
BMO Capital
Wolfe Research